Traceability and Product Identification Issues in Biosimilar PV Systems Traceability and Product Identification Issues in Biosimilar Pharmacovigilance Systems As regulatory scrutiny increases surrounding biosimilars, particularly in the realm of pharmacovigilance (PV), it is imperative for pharmaceutical and biotechnology professionals to accurately navigate the complexities of traceability and product identification. This tutorial serves as a comprehensive guide on best practices and regulatory requirements concerning pharmacovigilance for biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products. By following these steps, professionals will be well-positioned to maintain compliance with the U.S. Food and Drug Administration (FDA), as well as the relevant authorities…

Understanding Signal Detection Complexities for Specialty and Rare Disease Products Pharmacovigilance is an essential aspect of drug safety, particularly for specialty and rare disease products, including biosimilars, vaccines, and advanced therapy medicinal products (ATMPs). This tutorial will help professionals in clinical operations, regulatory affairs, and medical affairs navigate the complexities involved in signal detection for these unique products. We will examine important factors such as adverse event following immunization (AEFI), traceability, and immunogenicity, providing a comprehensive overview tailored to the US, UK, and EU markets. 1. Introduction to Signal Detection in Pharmacovigilance Signal detection in pharmacovigilance refers to the process…

<!– PV Expectations for Advanced Therapy Medicinal Products ATMPs and Gene Therapies –> Understanding Pharmacovigilance Expectations for Advanced Therapy Medicinal Products (ATMPs) and Gene Therapies Introduction to Pharmacovigilance in the Context of ATMPs Pharmacovigilance (PV), defined by the World Health Organization as the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, is an essential part of ensuring drug safety post-approval. This is particularly crucial for Advanced Therapy Medicinal Products (ATMPs) and gene therapies, which often present unique challenges. Regulatory authorities, including the US FDA, UK Medicines and Healthcare products…

Designing PV Systems for Vaccines—Including AEFI and Special Reporting Rules Designing Pharmacovigilance Systems for Vaccines: A Guide for Professionals Introduction to Pharmacovigilance in Vaccines Pharmacovigilance (PV) encompasses the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. In the context of vaccines, effective pharmacovigilance is particularly vital due to their role in public health and the potential for widespread, long-term effects. This guide serves as a step-by-step tutorial for professionals involved in the design and operation of PV systems specifically for vaccines, particularly in relation to the reporting of Adverse…

Pharmacovigilance challenges and strategies for biosimilars in US and EU Understanding Pharmacovigilance Challenges and Strategies for Biosimilars in the US and EU Introduction to Pharmacovigilance in the Context of Biosimilars Pharmacovigilance is the science surrounding the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. This area of study becomes increasingly complex when considering biosimilars—biologics that are highly similar to already-approved reference products. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both impose strict regulations regarding pharmacovigilance for biosimilars to ensure safety and efficacy. Understanding the nuances of pharmacovigilance as it…

Label and Product Information Design to Support Pharmacovigilance in Complex Therapies Pharmacovigilance (PV) is a crucial aspect of ensuring drug safety and efficacy, particularly for complex therapies such as biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products. The regulatory landscape surrounding these therapies is intricate, and compliance with the US FDA regulations is essential for market authorization and post-market compliance. This article provides a comprehensive, step-by-step tutorial on designing effective label and product information that supports robust pharmacovigilance practices. Understanding Pharmacovigilance Requirements Pharmacovigilance involves the science and activities related to the detection, assessment, understanding, and prevention of adverse…

Long-term Follow-Up in Pharmacovigilance for Cell and Gene Therapy The successful implementation of pharmacovigilance (PV) systems is essential for cell and gene therapies, particularly when it comes to understanding their long-term effects. These advanced therapies, classified as Advanced Therapy Medicinal Products (ATMPs), pose unique challenges in terms of monitoring safety and efficacy post-authorization. This article serves as a comprehensive guide for pharma professionals, clinical operations, regulatory affairs, and medical affairs professionals working within the US, UK, and EU. Here, we will detail the specific PV considerations for these therapies, focusing on long-term follow-up (LTFU), traceability, and safety registries. Understanding Pharmacovigilance…

Case studies of safety signals in biosimilars and their regulatory impact Case studies of safety signals in biosimilars and their regulatory impact Introduction to Pharmacovigilance in the Context of Biosimilars Pharmacovigilance is a vital component of drug safety management that entails the process of monitoring and assessing the safety profiles of pharmaceutical products, including biosimilars. By definition, biosimilars are biologic medical products highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency. The dynamic landscape of pharmacovigilance and the regulatory scrutiny surrounding these products necessitate a comprehensive understanding of how…

Risk minimisation for immunogenicity, infusion reactions and complex AEs Risk Minimization for Immunogenicity, Infusion Reactions and Complex Adverse Events Introduction to Pharmacovigilance in Biosimilars, Vaccines, ATMPs, and Specialty Products Pharmacovigilance is a critical aspect of drug development and commercialization, particularly for biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and other specialty products. The primary aim is to ensure drug safety and efficacy throughout the lifecycle of a product. As these therapies often target vulnerable populations, there exists an enhanced need for stringent monitoring and management of risks, notably immunogenicity and complex adverse events (AEs). In the United States, the FDA…

Active Safety Surveillance and Registries for Vaccines and ATMPs Pharmacovigilance plays an essential role in the post-marketing monitoring of vaccines and Advanced Therapy Medicinal Products (ATMPs). The need for robust safety surveillance mechanisms is particularly crucial for these products due to their unique characteristics, such as their complex production processes and potential implications for patient safety. This tutorial aims to provide a comprehensive guide to the regulatory frameworks, strategies for active safety surveillance, and the establishment of safety registries for these products, focusing primarily on the US, while making pertinent comparisons to the EU and UK frameworks. Understanding Pharmacovigilance in…